BR112021022831A2 - Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1 - Google Patents

Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1

Info

Publication number
BR112021022831A2
BR112021022831A2 BR112021022831A BR112021022831A BR112021022831A2 BR 112021022831 A2 BR112021022831 A2 BR 112021022831A2 BR 112021022831 A BR112021022831 A BR 112021022831A BR 112021022831 A BR112021022831 A BR 112021022831A BR 112021022831 A2 BR112021022831 A2 BR 112021022831A2
Authority
BR
Brazil
Prior art keywords
lag
administration
bispecific antibody
dosage regimens
regimens
Prior art date
Application number
BR112021022831A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Shepherd
Cristian Gradinaru
Daniel Gliddon
Fiona Germaschewski
Josefin-Beate Holz
Kin-Mei Leung
Louis Kayitalire
Michelle Morrow
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of BR112021022831A2 publication Critical patent/BR112021022831A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021022831A 2019-05-14 2020-05-14 Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1 BR112021022831A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
BR112021022831A2 true BR112021022831A2 (pt) 2022-01-18

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022831A BR112021022831A2 (pt) 2019-05-14 2020-05-14 Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1

Country Status (12)

Country Link
US (1) US20220275092A1 (https=)
EP (1) EP3969477A1 (https=)
JP (1) JP2022533578A (https=)
KR (1) KR20220008316A (https=)
CN (1) CN114206939A (https=)
AU (1) AU2020275209A1 (https=)
BR (1) BR112021022831A2 (https=)
CA (1) CA3139003A1 (https=)
IL (1) IL287979A (https=)
MX (1) MX2021013943A (https=)
SG (1) SG11202112136RA (https=)
WO (1) WO2020229626A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7850884B2 (ja) * 2021-03-31 2026-04-24 メルス・ベー・フェー 新規多重特異性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物

Also Published As

Publication number Publication date
JP2022533578A (ja) 2022-07-25
WO2020229626A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04
US20220275092A1 (en) 2022-09-01
IL287979A (en) 2022-01-01
KR20220008316A (ko) 2022-01-20
CN114206939A (zh) 2022-03-18
EP3969477A1 (en) 2022-03-23
SG11202112136RA (en) 2021-11-29
CA3139003A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
BR112021022831A2 (pt) Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
Higgins et al. Drug radiotherapy combinations: review of previous failures and reasons for future optimism
Nair et al. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
BR112022012437A2 (pt) Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
PE20180131A1 (es) Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112018075371A2 (pt) usos terapêuticos de um inibidor de c-raf
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112019010903A2 (pt) estrutura de cristal de gremlin-1 e anticorpo inibidor
Morris et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy
CR20250348A (es) ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-463)
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
Stamelos et al. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells
Daver et al. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options
Grabosch et al. PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer
BR112022021447A2 (pt) Moléculas de ligação para o tratamento de câncer
Braik et al. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy
CL2024001870A1 (es) Paradigma de tratamiento para una terapia con anticuerpos anti-cd19.
Auer et al. R2W: subcutaneous bortezomib, cyclophosphamide and rituximab (BCR) versus fludarabine, cyclophosphamide and rituximab (FCR) for initial therapy of Waldenstrőm’s macroglobulinemia: a randomised phase II study

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.